You are here

  • Home
  • Archive
  • Volume 11, Issue 5
  • Combined budesonide and formoterol for maintenance and relief provided better asthma control than budesonide for maintenance and terbutaline for relief

Article Text

Article menu
Download PDFPDF
Therapeutics
Combined budesonide and formoterol for maintenance and relief provided better asthma control than budesonide for maintenance and terbutaline for relief

http://dx.doi.org/10.1136/ebm.11.5.138

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Rabe KF, Pizzichini E, Ställberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006;129:246–56.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 Q In patients with mild to moderate asthma, what is the efficacy and safety of budesonide plus formoterol in a single inhaler for both maintenance therapy and symptom relief compared with budesonide for maintenance therapy plus terbutaline for symptom relief?

    Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Allergy & immunology ★★★★★★★ Respirology ★★★★★☆☆

    METHODS

    Embedded ImageDesign:

    randomised controlled trial.

    Embedded ImageAllocation:

    concealed (unclear).*

    Embedded ImageBlinding:

    blinded (patients).*

    Embedded ImageFollow up period:

    6 months.

    Embedded ImageSetting:

    77 centres in Argentina, Brazil, China, Denmark, Indonesia, Norway, the Philippines, Spain, and Sweden.

    Embedded ImagePatients:

    697 patients 11–79 years of age (mean age 38 y, 61% women) with asthma for ⩾6 months. Exclusion criteria included systemic corticosteroids or inhaled cromones in the past 30 days, recent respiratory infection, smoking history >10 pack years, and failure to complete a …

    View Full Text

    Footnotes

    • ↵* See glossary.

    • For correspondence: Dr K F Rabe, Leiden University Medical Centre, Leiden, The Netherlands. K.F.Rabe{at}lumc.nl

    • Source of funding: AstraZeneca.

    Linked Articles

    • Glossary
      Glossary
      BMJ Publishing Group Ltd
      BMJ Evidence-Based Medicine 2006; 11 159a-159a Published Online First: 29 Sep 2006. doi: 10.1136/ebm.11.5.159a